title: [Clinical effects of a combination treatment with fosfomycin and clavulanic acid/ticarcillin for infections in patients complicated with hematological disorders].
abstract: We evaluated clinical effects and toxicities of a combination of fosfomycin (FOM) and clavulanic acid/ticarcillin (CVA/TIPC) for treatment of infections complicated with hematological disorders in 61 patients. Fifty-eight patients were evaluable, including 40 with acute leukemia, 13 with malignant lymphoma and 5 with other hematological disorders. Clinical efficacies were excellent in 21 cases, good in 13 cases, fair in 2 cases and poor in 22 cases. The efficacy rate was 58.6% (34 cases/58 cases). This treatment was also effective in 12 of 20 cases in which granulocyte counts were less than 500/microliters through the course of administration. No subjective side effects were observed. Abnormal values in laboratory tests were noted in 1 case. Mild elevations of GOT and GPT were observed. Thus, the combination of FOM and CVA/TIPC is an effective and safe regimen for the treatment of infections in patients complicated with hematological disorders.
authors.affiliation: Third Department of Internal Medicine, Kyoto Prefectural University of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Hirakawa
authors.forename: S
authors.initials: S
authors.lastname: Tsuda
authors.forename: S
authors.initials: S
authors.lastname: Misawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ueda
authors.forename: H
authors.initials: H
authors.lastname: Kaneko
authors.forename: M
authors.initials: M
authors.lastname: Nakao
authors.forename: Y
authors.initials: Y
authors.lastname: Ariyama
authors.forename: H
authors.initials: H
authors.lastname: Nakai
authors.forename: T
authors.initials: T
authors.lastname: Seriu
authors.forename: T
authors.initials: T
authors.lastname: Takashima
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage*; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D013982:Ticarcillin / Q000008:administration & dosage
chemical_list: D002969:Clavulanic Acids; D019818:Clavulanic Acid; D005578:Fosfomycin; D013982:Ticarcillin